Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 3

Sponsor Class

OTHER 1728INDUSTRY 713NIH 341NETWORK 159OTHER_GOV 32FED 4UNKNOWN 3INDIV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 42Esophageal Neoplasms 24Stomach Neoplasms 21Rectal Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Colorectal Neoplasms 12Neoplasms 10Lung Neoplasms 10Brain Neoplasms 10Triple Negative Breast Neoplasms 9Small Cell Lung Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Hepatocellular 5Recurrence 4Radiation Injuries 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Meningeal Carcinomatosis 3Lymphoma 3Leukemia, Myeloid, Acute 3Hormone Receptor Positive Advanced Breast Cancer 3HER2-positive Breast Cancer 3Colonic Neoplasms 3Vomiting 2

Interventions

Rituximab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
UNKNOWN × Lymphoma × Clear all
NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04511351 2020-08-13

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

ChineseAMS

Phase NA Unknown
76 enrolled
Lymphoid

Lymphoma

NCT03731390 2018-11-06

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

ChineseAMS

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡